Inhalable Bifunctional sEH/COX-2 Inhibitors for Treatment of Asthma
Time: 1:30 pm
day: Conference Day 2
Details:
- Developing inhalable bifunctional sEH/COX-2 small molecule inhibitors with novel mechanisms of action to treat Asthma
- Asthma affects over 300 million people worldwide and up to 55% of these patients experience recurrent episodes of bronchospasm despite long-acting beta-agonists plus high-dose inhaled or oral corticosteroids
- Chronic use of corticosteroids can lead to immune suppression, CVD risk, glaucoma, bone loss and myopathy, while alternative new therapies including biologics are expensive and cause adverse side effects
